Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white
Drugs

Spironolactone-Darnitsa

Potassium-sparing diuretics. Aldosterone antagonists. Spironolactone

The active substance of the medicine, spironolactone, is a competitive aldosterone antagonist that affects the distal convoluted tubules. Due to blocking aldosterone, spironolactone suppresses water and Na+ ion retention and promotes the retention of K+ ions, which not only increases the excretion of Na+ and Cl− ions and decreases the excretion of K+ ions with urea, but also reduces the excretion of H+ ions.

– Primary hyperaldosteronism.
– Congestive heart failure — if other diuretics are ineffective or not tolerated, or if their efficacy needs to be enhanced.
– Essential hypertension, mainly with hypokalemia — usually in combination with other antihypertensive drugs.
– Hepatic cirrhosis accompanied by oedema and/or ascites.
– Oedemas caused by nephrotic syndrome.
– Hypokalemia — if other therapy is not possible.
– Prevention of hypokalemia in patients who receive cardiac glycosides — if other methods of therapy are considered inappropriate or inadvisable.

The medicine should be used orally in adults and children. The daily dose of the medicine should be taken in 1 or 2 doses after meals. The daily dose if it is taken once, or the first dose if the medicine is taken twice, is recommended in the morning.

Specialized edition for medical institutions and doctors.